Luncheon Seminar 1 Live
Oct. 1 (Thu.) 11:50-12:40 Room 3 RIHGA Royal Hotel Hiroshima 4F Crystal Hall
LS-1 Treatment and resistance of lung cancer with driver mutations
| Chair | Hirotoshi Akita | (Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University) |
|---|---|---|
| Speaker | Seiji Yano | (Division of Medical Oncology Cancer Research Institute, Kanazawa University) |
Co-sponsored by: Chugai Pharmaceutical Co., LTD.
Luncheon Seminar 2 Live / On Demand
Oct. 1 (Thu.) 11:50-12:40 Room 4 RIHGA Royal Hotel Hiroshima 3F Miyajima
LS-2
A novel three-dimensional culture for cancer research - Tissueoid cell culture system
| Chair | Satoshi Fujii | (Department of Molecular Pathology, Yokohama City University Graduate School of Medicine) |
|---|---|---|
| Speaker | Ken-ichi Mukaisho | (Division of Human Pathology, Department of Pathology, Shiga University of Medical Science) |
Co-sponsored by: Japan Vilene Company, Ltd.
Luncheon Seminar 3 Live / On Demand
Oct. 1 (Thu.) 11:50-12:40 Room 5 RIHGA Royal Hotel Hiroshima 3F Seto
LS-3
The Breakthrough of BCMA-Targeted Immunotherapy in Treating Multiple Myeloma
| Chair | Alex Liu | (GenScript Corporation) |
|---|---|---|
| Speaker | Frank Fan | (Legend Biotech Inc.) |
Co-sponsored by: GenScript Corporation
Luncheon Seminar 4 Live
Oct. 1 (Thu.) 11:50-12:40 Room 7 HOTEL MIELPARQUE Hiroshima 6F Zuiun 1
LS-4
Utility of CDK4/6 inhibitors in the treatment of breast cancer: from bench to clinics
| Chair | Maki Tanaka | (JCHO Kurume General Hospital) |
|---|---|---|
| Speaker | Junichi Kurebayashi | (Department of Breast and Thyroid Surgery, Kawasaki Medical School) |
Co-sponsored by: Eli Lilly Japan K.K.
Luncheon Seminar 5 Live / On Demand
Oct. 1 (Thu.) 11:50-12:40 Room 8 HOTEL MIELPARQUE Hiroshima 6F Zuiun 2
LS-5
| Chair | Yoshikatsu Koga | (Exploratory Oncology Research & Clinical Trial Center, National Cancer Center) |
|---|
Introduction of Fukushima patient derived tumor xenograft (F-PDX®)
| Speaker1 | Motoki Takagi | (Fukushima Medical University / Fukushima Translational Research Foundation) |
|---|
Current status and perspectives of patient-derived rare cancer models
| Speaker2 | Tadashi Kondo | (Division of Rare Cancer Research, National Cancer Center Research Institute) |
|---|
Co-sponsored by: Charles River Laboratories Japan, INC
Evening Seminar 1 Live / On Demand
Oct. 1 (Thu.) 15:30-16:20 Room 7 HOTEL MIELPARQUE Hiroshima 6F Zuiun 1
ES-1 The insider’s guide to Nature Cancer
| Moderator | Sayaka Yamane | (Institutional Marketing, Springer Nature) |
|---|---|---|
| Speaker | Alexia-Ileana Zaromytidou | (Nature Cancer, Nature Research) |
Co-sponsored by: Springer Nature
Luncheon Seminar 14 Live / On Demand
Oct. 2 (Fri.) 11:50-12:40 Room 2 RIHGA Royal Hotel Hiroshima 4F Royal Hall 3
LS-14 Single-cell landscape of antitumor immune responses
| Chair | Ken Osaki | (10x Genomics) |
|---|---|---|
| Speaker | Hiroshi Kagamu | (Department of Respiratory Medicine, Saitama Medical University International Medical Center) |
Co-sponsored by: Scrum Inc./ 10x Genomics
Luncheon Seminar 6 Live / On Demand
Oct. 2 (Fri.) 11:50-12:40 Room 3 RIHGA Royal Hotel Hiroshima 4F Crystal Hall
LS-6
Multi-parametric analysis of antigen-specific T cells by using a super-multicolor flow cytometry
| Chair | Keisuke Yuki | (BD Biosciences) |
|---|---|---|
| Speaker | Hideki Ueno | (Department of Immunology, Graduate School of Medicine, Kyoto University) |
Co-sponsored by: Nippon Becton Dickinson Company, Ltd.
Luncheon Seminar 7 Live / On Demand
Oct. 2 (Fri.) 11:50-12:40 Room 4 RIHGA Royal Hotel Hiroshima 3F Miyajima
LS-7
| Chair | Tadashi Kondo | (National Cancer Center Research Institute) |
|---|
An in vitro system for evaluating anti-cancer drugs using patient-derived tumor organoids (F-PDO®)
| Speaker | Motoki Takagi | (Fukushima Medical University) |
|---|
Co-sponsored by: FUJIFILM Wako Pure Chemical Corporation
Luncheon Seminar 8 Live
Oct. 2 (Fri.) 11:50-12:40 Room 7 HOTEL MIELPARQUE Hiroshima 6F Zuiun 1
LS-8 Management and selection method of advanced gastric cancer chemotherapy
| Chair | Tatsuya Ioka | (Yamaguchi University Hospital, Department of Oncology Center) |
|---|---|---|
| Speaker | Hiroaki Tanioka | (Department of Clinical Oncology, Kawasaki Medical School) |
Co-sponsored by: TAIHO PHARMACEUTICAL CO., LTD.
Luncheon Seminar 9
Oct. 3 (Sat.) 11:50-12:40 Room 3 RIHGA Royal Hotel Hiroshima 4F Crystal Hall
LS-9 Development of cancer immunotherapy based on immunogenome analysis
| Chair | Takuya Tsunoda | (Division of Medical Oncology, Department of Medicine, Showa University School of Medicine) |
|---|---|---|
| Speaker | Hiroyoshi Nishikawa | (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center, National Cancer Center / Department of Immunology, Nagoya University Graduate School of Medicine) |
Co-sponsored by: MSD K.K.
Luncheon Seminar 10 Live / On Demand
Oct. 3 (Sat.) 11:50-12:40 Room 4 RIHGA Royal Hotel Hiroshima 3F Miyajima
LS-10 Advanced T Cell Analytics Using Digital Cell Biology at Light Speed
| Chair | Yasujiro Kiyota | (Nikon Corporation) |
|---|---|---|
| Speaker | Yue Geng | (Berkeley Lights Inc.) |
Co-sponsored by: Nikon Corporation
Luncheon Seminar 11 Live / On Demand
Oct. 3 (Sat.) 11:50-12:40 Room 5 RIHGA Royal Hotel Hiroshima 3F Seto
LS-11 RNA Expression and Methylation in Liquid Biopsy
| Chair | Takahiro Ochiya | (Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University) |
|---|---|---|
| Speaker | Hideshi Ishii | (Department of Medical Data Science, Graduate School of Medicine, Osaka University) |
Co-sponsored by: Toray Industries, Inc,
Luncheon Seminar 12 Live / On Demand
Oct. 3 (Sat.) 11:50-12:40 Room 7 HOTEL MIELPARQUE Hiroshima 6F Zuiun 1
LS-12 Cancer Genomics -implication of whole genome sequencing-
| Chair | Hideki Hanaoka | (Regional Segment Marketing, Illumina K.K.) |
|---|---|---|
| Speaker | Ken Yamaguchi | (Shizuoka Cancer Center) |
Co-sponsored by: Illumina K.K.
Luncheon Seminar 13 Live
Oct. 3 (Sat.) 11:50-12:40 Room 8 HOTEL MIELPARQUE Hiroshima 6F Zuiun 2
LS-13 Development of treatment strategy for HER2-positive breast cancer
| Chair | Masakazu Toi | (Kyoto University) |
|---|---|---|
| Speaker | Yasuo Miyoshi | (Department of Breast and Endocrine Surgery Hyogo, College of Medicine) |
Co-sponsored by: DAIICHI SANKYO COMPANY, LIMITED
